Skip to search formSkip to main contentSkip to account menu

ABT-925

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
ABT-925, a selective dopamine D3 receptor (DRD3) antagonist, was tested in schizophrenia. A DRD3 gene polymorphism results in an… 
Review
2012
Review
2012
The potential of D3 receptor antagonism to treat positive, negative, and cognitive symptoms of schizophrenia is reviewed on the… 
2011
2011
There is substantial preclinical and clinical evidence to suggest a potential role for the dopamine D3 receptor in the treatment… 
Highly Cited
2010
Highly Cited
2010
Dopamine D3 receptors are preferentially localized in the limbic system and midbrain, and thus may be involved in the… 
2010
2010
Dopamine D3 receptors (D3Rs) may afford the ability to treat a wide variety of neuropsychiatric disorders (Graff-Guerrero et al… 
2010
2010
  • 2010
  • Corpus ID: 18695494
Dopamine D3 receptors (D3Rs) may afford the ability to treat a wide variety of neuropsychiatric disorders (Graff-Guerrero et al…